Perseus Proteomics : (Amendments) Amendments to “Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2022

June 23, 2022

Perseus Proteomics Inc.

Securities Code: 4882 Growth TSE

To all stakeholders,

(Amendments) Amendments to "Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2022"

Perseus Proteomics Inc. ("the Company") hereby announces amendments to "Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2022" announced on May 13, 2022. The amended parts are underlined.

1. Reasons for amendments
   The Company has found some errors in"Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2022" after submission and now makes amendments.
2. Amendment details
3. 1. Page 3 (1) Overview of business results of the fiscal year ended March 31, 2022 (Before amendment)
      d. PPMX-T001

PPMX-T001 targets GPC3 which is highly expressed on lever cancer. Chugai Pharmaceutical Co., Ltd. (Chugai) was provided the rights to register the patents in 2006 and has been developing it in 2 different forms of a drug for lever cancer: GC33 and ERY974, however, the patent which is a subject of the agreement will expire on June 20, 2022. Accordingly, the agreement will terminate on the same date. There is no impact on the future income/profit of the Company from PPMX-T001 and the Company does not estimate any impact in its plan.

(After amendment) d. PPMX-T001

PPMX-T001 targets GPC3 which is highly expressed on lever cancer. Chugai Pharmaceutical Co., Ltd. (Chugai) was provided the rights to register the patents in 2006 and has been developing it in 2 different forms of a drug for lever cancer: GC33 and ERY974, however, the patent which is a subject of the agreement will expire on June 21, 2022. Accordingly, the agreement will terminate on the same date. There is no impact on the future income/profit of the Company from PPMX-T001 and the Company does not estimate any impact in its plan.

1 / 3

1. Page 5 2. Non-consolidated financial statements (1) Statement of balance sheet
   (Before amendment)

		(thousand yen)
	As of March 31, 2021	As of March 31, 2022
Non-current assets
Property, plant and equipment
Buildings	8,034	13,860
Accumulated depreciation	(8,034)	(13,860)
Buildings, net	0	0
Tools, furniture and fixtures	114,952	278,388
Accumulated depreciation	(114,952)	(278,387)
Tools, furniture and fixtures, net	0	0
Total property, plant and equipment	0	0

(After amendment)

		(thousand yen)
	As of March 31, 2021	As of March 31, 2022
Non-current assets
Property, plant and equipment
Buildings	8,034	8,043
Accumulated depreciation	(8,034)	(8,043)
Buildings, net	0	0
Tools, furniture and fixtures	114,952	115,594
Accumulated depreciation	(114,952)	(115,594)
Tools, furniture and fixtures, net	0	0
Total property, plant and equipment	0	0

(3) Page 7 (2) Statement of income

(Before amendment)

			(thousand yen)
	Fiscal year ended		Fiscal year ended
	March 31, 2021		March 31, 2022
Non-operating expenses
Commission expenses	4,433	－
Taxes and dues	3,527	9,346
Listing expenses	3,436	9,531
Other	0	0
Total non-operating expenses	11,397	18,878

2 / 3

(After amendment)

			(thousand yen)
	Fiscal year ended		Fiscal year ended
	March 31, 2021		March 31, 2022
Non-operating expenses
Commission expenses	4,433	－
Taxes and dues	3,527	9,346
Listing expenses	3,436	9,531
Other	-	0
Total non-operating expenses	11,397	18,878

END

3 / 3